[{"Assets_0_Q2_USD":308814000.0,"CommonStockSharesOutstanding_0_Q2_shares":27036652.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":37682000.0,"NetIncomeLoss_2_Q2_USD":33158000.0,"NetIncomeLoss_1_Q2_USD":-54221000.0,"StockholdersEquity_0_Q2_USD":129334000.0,"EarningsPerShareBasic_2_Q2_USD":1.23,"EarningsPerShareBasic_1_Q2_USD":-2.01,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":26968818.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":26906149.0,"Ticker":"ESPR","CIK":"1434868","name":"ESPERION THERAPEUTICS, INC.","OfficialName":"Esperion Therapeutics Inc. Common Stock","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"302940173.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20190808"}]